Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jeannette Gerspach"'
Publikováno v:
BioFactors. 35:364-372
Tumor necrosis factor (TNF) is highly pleiotropic cytokine regulating diverse cellular processes such as proliferation, cell migration, angiogenesis, differentiation, apoptosis, necrosis, but also survival. Because of its name-giving tumor necrosis-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f60ae23d9ff2d40e75eae10717227b
https://doi.org/10.1002/biof.50
https://doi.org/10.1002/biof.50
Autor:
Ingo Grunwald, Marie Kühnle, Klaus Pfizenmaier, Anja Krippner-Heidenreich, Theobald Sterns, Gudrun Zimmermann, Jeannette Gerspach, Daniela N. Männel, Peter Scheurich, Steve D. Shnyder, Jason H. Gill
Publikováno v:
The Journal of Immunology. 180:8176-8183
The inflammatory and proapoptotic cytokine TNF possesses a compelling potential as an antitumoral therapeutic agent. Possible target cells include the malignant cells themselves, the tumor vasculature, or the immune system. As the clinical use of TNF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c038b140b249af287a7bc7af05f2677
https://doi.org/10.4049/jimmunol.180.12.8176
https://doi.org/10.4049/jimmunol.180.12.8176
Autor:
J Nemeth, Harald Wajant, Dafne Müller, A Menrad, H Petrul, Olaf Selchow, M Noack, Sabine Münkel, Jeannette Gerspach, Klaus Pfizenmaier
Publikováno v:
Cell Death & Differentiation. 13:273-284
Tumor necrosis factor (TNF) prodrugs are fusion proteins comprised of an N-terminal single-chain antibody variable fragment (scFv) targeting a TNF effector and a C-terminal TNF receptor (TNFR)1-derived inhibitor module. Introduction of matrix metallo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a25bbf86df7dce6ccd0340a86ab3a2a3
https://doi.org/10.1038/sj.cdd.4401735
https://doi.org/10.1038/sj.cdd.4401735
Publikováno v:
Cytokine & Growth Factor Reviews. 16:55-76
Due to their strong apoptosis-inducing capacity, the death receptor ligands CD95L, TNF and TRAIL have been widely viewed as potential cancer therapeutics. While clinical data with CD95L and TRAIL are not yet available, TNF is a registered drug, albei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5faf2baf7f47fa33eaa3f823d3defaf
https://doi.org/10.1016/j.cytogfr.2004.12.001
https://doi.org/10.1016/j.cytogfr.2004.12.001
Autor:
Klaus Pfizenmaier, Debola Banerjee, Jeannette Gerspach, Dieter Moosmayer, Elke Gerlach, Thomas Wüest
Publikováno v:
Oncogene. 21:4257-4265
We describe a TNF fusion protein designated TNF-Selectokine, which is a homo-trimeric molecule comprised of a single chain antibody (scFv) targeting module, a trimerization domain and TNF. TNF-Selectokine exerts high bioactivity towards the targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02085fb78aeb60831a60d6a1d33288b
https://doi.org/10.1038/sj.onc.1205193
https://doi.org/10.1038/sj.onc.1205193
Autor:
Carmen Kolle, Matthias Grell, Gudrun Zimmermann, Jeannette Gerspach, Heiner Böttinger, Alex Götz
Publikováno v:
Microscopy Research and Technique. 50:243-250
Tumor necrosis factor (TNF) exists in two bioactive forms, the membrane integrated form and the proteolytically derived soluble cytokine. Both forms of TNF are involved in a variety of different physiological and pathophysiological situations. Here w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab315f41a5914e3d8860001efcd425ca
https://doi.org/10.1002/1097-0029(20000801)50:3<243::aid-jemt8>3.0.co
https://doi.org/10.1002/1097-0029(20000801)50:3<243::aid-jemt8>3.0.co
Autor:
Jeannette Gerspach, Matthias Klein, Klaus Pfizenmaier, Christian Bayertz, Ulrich L. M. Eisel, Anja van der Ploeg, Isabelle Pieri
Publikováno v:
European Journal of Neuroscience. 11:2083-2092
We have cloned the 5'-region of the murine N-methyl-D-aspartate (NMDA) receptor channel subunit NR2C (GluRe3) gene and characterized the cis- and trans-activating regulatory elements responsible for its tissue specific activity. By using a native e3-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b993c427d2bb378de6fbf02ac41b2c7
https://doi.org/10.1046/j.1460-9568.1999.00629.x
https://doi.org/10.1046/j.1460-9568.1999.00629.x
Publikováno v:
Recent patents on anti-cancer drug discovery. 6(3)
The death receptors CD95, TRAILR1 and TRAILR2 induce cell death in many types of tumor cells. Activation of these receptors has received considerable interest due to its potential use in cancer therapy. In particular the observation that most primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f17b341f2f38d99433d0cc7ec366f1ad
https://pubmed.ncbi.nlm.nih.gov/21762072
https://pubmed.ncbi.nlm.nih.gov/21762072
Autor:
Jeannette, Gerspach, Britta, Schneider, Nicole, Müller, Tina, Otz, Harald, Wajant, Klaus, Pfizenmaier
Publikováno v:
Advances in experimental medicine and biology. 691
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::419aeccedbb189dece817e26369b4d4d
https://pubmed.ncbi.nlm.nih.gov/21153356
https://pubmed.ncbi.nlm.nih.gov/21153356
Publikováno v:
Cancer letters. 332(2)
CD95, TNFR1, TRAILR1 and TRAILR2 belong to a subgroup of TNF receptors which is characterized by a conserved cell death-inducing protein domain that connects these receptors to the apoptotic machinery of the cell. Activation of death receptors in mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::951131dc7f3b4ea2b3c55e939ee56e6e
https://pubmed.ncbi.nlm.nih.gov/21236560
https://pubmed.ncbi.nlm.nih.gov/21236560